JAZZ News and Press, Jazz Pharmaceuticals plc From 03/21/23

2023-03-21 06:45:00 ET A few years ago, the cannabis industry attracted much interest from investors following significant regulatory changes in Canada and anticipated progress elsewhere in developed countries. However, this interest has now died down, and many of the major companies in the...

2023-03-12 13:42:22 ET Summary Avadel Pharmaceuticals' Lumryz has the potential to transform the narcolepsy treatment market. Avadel estimates that the total potential patient population for Lumryz could be greater than 30,000, with a market opportunity of over $3.0 billion annual...

2023-03-09 14:52:53 ET Summary Given that Axsome Therapeutics, Inc. is launching Auvelity with a small in-house team, you can expect a substantial sales increase in the next three years. In a highly favorable deal, Axsome recently out-licensed its ex-USA rights of Sunosi to Pharma...

Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes Canada NewsWire MISSISSAUGA, ON , ...

2023-03-07 09:35:38 ET Summary Avadel's narcolepsy treatment Lumryz has tentative FDA approval pending final approval, which is delayed due to a patent dispute that has since been resolved. Lumryz is a once-at-bedtime narcolepsy treatment using Avadel's drug-delivery tech, differe...

Summary Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a common movement disorder affecting 4% of adults > 40. Current treatments like be...

The US Drug Enforcement Agency has determined that MyMD Pharmaceuticals ( NASDAQ: MYMD ) experimental cannabinoid Supera-CBD is not a controlled substance. The candidate is under development for anxiety, pain, addiction, and seizures. Presently, with the exception of Jazz Pharmace...

Jazz Pharmaceuticals plc (JAZZ) Q4 2022 Earnings Conference Call March 01, 2023, 04:30 PM ET Company Participants Darren Fox - Executive Director of Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Dan Swisher - President and Chief Operating Offic...

While Jazz Pharmaceuticals ( NASDAQ: JAZZ ) missed on the top and bottom lines in its Q4 2022 results, its 2023 revenue outlook range included the consensus. The company is projecting 2023 total revenue of $3.675M to $3.875M (consensus $3.76B). Shares are up 5% in after-hours ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2022 Q4 earnings call. For further details see: Jazz Pharmaceuticals plc 2022 Q4 - Results - Earnings Call Presentation